TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis

Oncogene

Volumn 25, Issue 4, 2006, Pages 650-655

  Cruz Munoz W ^a   Kim, I ^b   Khokha, R ^a,b  

^a Department of Laboratory Medicine and Pathobiology ^*  (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; B16F10; Host stroma; Teratoma; TIMP 3

Indexed keywords

CD31 ANTIGEN; GELFOAM; MATRIGEL; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CARCINOGENESIS; CELL CLONING; CONTROLLED STUDY; ENDOTHELIUM CELL; KNOCKOUT GENE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TERATOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; WILD TYPE;

ANIMALS; ANTIGENS, CD31; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TERATOMA; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

ANIMALIA; MUS MUSCULUS;

EID: 31544476294     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209104     Document Type: Article

References (44)

1. Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B et al. (1996). Biochem Cell Biol 74: 853-862.
2. Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G et al. (1997). Invest Ophthalmol Vis Sci 38: 817-823.
3. Andreu T, Beckers T, Thoenes E, Hilgard P, von Melchner H. (1998). J Biol Chem 273: 13848-13854.
4. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK et al. (1999). Cancer Res 59: 798-802.
5. Bian J, Wang Y, Smith M. (1996). Carcinogenesis 17: 1805-1811.
6. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP et al. (2001). Cancer Res 61: 2189-2193.
7. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG et al. (1996). Cell 85: 683-963.
8. Chan VT, Zhang DN, Nagaravapu U, Hultquist K, Romero LI, Herron GS. (1998). J Invest Dermatol 111: 1153-1159.
9. Coussens LM, Fingleton B, Matrisian LM. (2002). Science 295: 2387-2392.
10. DeClerck YA. (2000). Eur J Cancer 36: 1258-1268.
11. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ et al. (2004). Clin Cancer Res 10: 3972-3979.
12. Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G et al. (2001). J Clin Invest 108: 831-841.
13. Folkman J. (2002). Semin Oncol 29: 15-18.
14. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. (1998). Cancer Res 58: 1048-1051.
15. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK et al. (2005). Circ Res 97: 380-390.
16. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S et al. (2001). FEBS Lett 508: 187-190.
17. Kleiner DE, Stetler-Stevenson WG. (1999). Cancer Chemother Pharmacol 43(Suppl): S42-S51.
18. Kruger A, Fata JE, Khokha R. (1997). Blood 90: 1993-2000.
19. Leco KJ, Waterhouse P, Sanchez OH, Gowing KL, Poole AR, Wakeham A et al. (2001). J Clin Invest 108: 817-829.
20. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A et al. (2005). J Clin Oncol 23: 2831-2839.
21. Loging WT, Reisman D. (1999). Oncogene 18: 7608-7615.
22. Lynch CC, Matrisian LM. (2002). Differentiation 70: 561-573.
23. Martin DC, Ruther U, Sanchez-Sweatman OH, Orr FW, Khokha R. (1996). Oncogene 13: 569-576.
24. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C et al. (2005). FASEB J 19: 234-236.
25. McCarty MF, Baker CH, Bucana CD, Fidler IJ. (2002). Int J Oncol 21: 5-10.
26. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M et al. (1999). J Clin Oncol 17: 1802-1808.
27. Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K et al. (2000). Int J Cancer 88: 575-578.
28. Murphy G, Knauper V, Lee MH, Amour A, Worley JR, Hutton M et al. (2003). Biochem Soc Symp 70: 65-80.
29. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. (1994). Cell 79: 315-328.
30. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA et al. (1992). Lab Invest 67: 519-528.
31. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M et al. (2003). Nat Med 9: 407-415.
32. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N et al. (2000). Int J Cancer 89: 118-121.
33. Sang QX. (1998). Cell Res 8: 171-177.
34. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. (1994). Nature 370: 61-65.
35. Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S et al. (2003). Cancer 98: 1822-1829.
36. Soloway PD, Alexander CM, Werb Z, Jaenisch R. (1996). Oncogene 13: 2307-2314.
37. Spurbeck WW, Ng CY, Strom T, Vanin E, Davidoff A. (2002). Blood 100: 3361-3368.
38. Spurbeck WW, Ng CY, Vanin EF, Davidoff AM. (2003). Cancer Gene Ther 10: 161-167.
39. Sternlicht MD, Werb Z. (2001). Annu Rev Cell Dev Biol 17: 463-516.
40. Sun Y, Hegamyer G, Kim H, Sithanandam K, Li H, Watts R et al. (1995). J Biol Chem 270: 19312-19319.
41. Sun Y, Kim H, Parker M, Stetler-Stevenson WG, Colburn NH. (1996). Anticancer Res 16: 1-7.
42. Thurston G, Baluk P, Hirata A, McDonald DM. (1996). Am J Physiol 271: H2547-H2562.
43. Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B et al. (2003). J Clin Endocrinol Metab 88: 1367-1373.
44. Yu WH, Yu S, Meng Q, Brew K, Woessner Jr JF. (2000). J Biol Chem 275: 31226-31232.